KYMR — Kymera Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $6.38bn
- $5.54bn
- $39.21m
Annual income statement for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 72.8 | 46.8 | 78.6 | 47.1 | 39.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 173 | 208 | 244 | 309 | 389 |
| Operating Profit | -101 | -161 | -166 | -262 | -349 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -100 | -155 | -147 | -224 | -311 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -100 | -155 | -147 | -224 | -311 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -100 | -155 | -147 | -224 | -311 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -100 | -155 | -147 | -224 | -311 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.09 | -2.87 | -2.52 | -2.92 | -3.64 |